title: [Are measles and mumps vaccinations worth while in Switzerland?].
abstract: Cost-benefit analyses have been performed in investigating the usefulness of general vaccination against measles and mumps in all children. Even by a conservative reckoning the cost of general measles immunization for all children in the second year of life is much lower than the financial effects of the disease. In the case of general mumps vaccination, cost-benefit analyses fo not give so significant an outweight of financial benefit as for measles vaccination. If only for economic reasons, however, general immunization against mumps is recommended for all children in the second year of life. From the economic viewpoint, general immunization programs for teenagers do not pay either with regard to mumps or measles. Such vaccinations may of course be recommended on an individual basis, especially for teenagers with a negative measles history.
mesh_terms: D000293:Adolescent; D003362:Cost-Benefit Analysis; D004469:Economics, Hospital; D005260:Female; D006699:Home Care Services / Q000191:economics; D006801:Humans; D007223:Infant; D008297:Male; D008457:Measles / Q000191:economics; D008458:Measles Vaccine / Q000627:therapeutic use*; D009107:Mumps / Q000191:economics; D009108:Mumps Vaccine / Q000627:therapeutic use*
chemical_list: D008458:Measles Vaccine; D009108:Mumps Vaccine
vernacular_title: Rentiert die Masern- und/oder Mumps- Impfung für schweizerische Verhältnisse?